Harnessing Real-World Evidence for the Development of Novel Cancer Therapies

Khozin, 2019, Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer, Cancer, 125, 4019, 10.1002/cncr.32383 Santiago-Walker, 2019, Predictive value of fibroblast growth factor receptor mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients with advanced urothelial cancer, J. Clin. Oncol., 7, 419, 10.1200/JCO.2019.37.7_suppl.419 Parkin, 2006, The evolution of the population-based cancer registry, Nat. Rev. Cancer, 6, 603, 10.1038/nrc1948 Loda, 2019, Exploration of artificial intelligence use with ARIES in multiple myeloma research, J. Clin. Med., 8, 999, 10.3390/jcm8070999 Stewart, 2019, An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non–small-cell lung cancer, JCO Clin. Cancer Inform., 3, 1, 10.1200/CCI.18.00155 Mitchell, 2015, Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice, J. Oncol. Pract., 11, 491, 10.1200/JOP.2015.004929 Raphael, 2020, Real-world evidence and regulatory drug approval, Nat. Rev. Clin. Oncol., 17, 271, 10.1038/s41571-020-0345-7 Khozin, 2019, Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs), J. Clin. Oncol., 37, 110, 10.1200/JCO.2019.37.15_suppl.110 Agrawal, 2020, Machine learning imputation of Eastern Cooperative Oncology Group performance status (ECOG PS) scores from data in CancerLinQ discovery, J. Clin. Oncol., 38, 10.1200/JCO.2020.38.15_suppl.e19318 Conley, 2017, Core clinical data elements for cancer genomic repositories: a multi-stakeholder consensus, Cell, 171, 982, 10.1016/j.cell.2017.10.032 Agrawal, 2019, Development of an artificial intelligence model to predict survival at specific time intervals for lung cancer patients, J. Clin. Oncol., 37, 6556, 10.1200/JCO.2019.37.15_suppl.6556 Dickson, 2020, The master observational trial: a new class of master protocol to advance precision medicine, Cell, 180, 9, 10.1016/j.cell.2019.12.009 Chan, 2020, Developing a framework to incorporate real-world evidence in cancer drug funding decisions: The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, BMJ Open, 10, 10.1136/bmjopen-2019-032884 Gottlieb, 2018 Tallent, 2017